newsfilter
← Latest News
GlobeNewswire·

Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates

Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Nov. 04,